Ask AI
ProCE Banner Series

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

Learning Objectives

  • Review FL disease state and unmet needs
  • Examine the study design and efficacy of MONJUVI+ R2, a CD19 and CD20-targeted immunotherapy combination
  • Cover safety and dosing of MONJUVI + R2

All Events

Upcoming Events

October

28

2026

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Past Events

March

04

2026

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

May

27

2026

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

August

19

2026

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte